Download
1 / 17
170 likes | 269 Views
Patented new treatment scheme for type-1 diabetes – generating additional sales with existing pharmaceuticals. ● Düsseldorf/Melbourne, 2010. An opportunity to generate addition sales.
E N D
Patented new treatment scheme for type-1 diabetes –generating additional sales with existing pharmaceuticals • ● Düsseldorf/Melbourne, 2010
An opportunity to generate addition sales • BvA-TeC is a start-up company which will give type-1 and type-1.5 diabetes patients worldwide access to a new, patented treatment scheme. • 80% of patients were able to stop taking artificial insulin after completing the treatment. • Current potential for the treatment scheme is at about 90 million patients worldwide (diabetes type1- and type-1.5). Due to aging, sedentary lifestyle and unhealthy diets the number of diabetes patients is rising worldwide. • The treatment scheme is based on combined use of existing medications: Bacillus Calmette-Guérin (BCG), Famciclovir, Fragmin-D, Alpha-antitrypsin, Interleukin-12. • Pharmaceutical companies, who produce the pharmaceuticals used in the treatment scheme, get the opportunity to generate additional turnover of about 57 billion Euros within the next 10 years.
Treatment scheme • Result of 20 years of research and development work by German scientist Prof. Ulrich von Arnim • Stopping the immune reaction against the insulin-producing islet cells by reprogramming natural killer T-cells, so the body can produce new islet cells that settle in the pancreas and produce insulin. • 80% of patients were able to stop taking artificial insulin – dramatically improved lifestyle quality for patients Prof. Ulrich von Arnim
Treatment scheme: Medications used • Scheme uses a combination therapy of already existing medications • Bacillus Calmette-Guérin (BCG) • Famciclovir • Fragmin-D • Alpha-antitrypsin • Interleukin-12 • Total cost of medications of about 17,000 Euros per treatment/patient in 12 months
Treatment scheme: Efficacy proved in clinical studies Studies were conducted jointly with the Universities of Tübingen and Heidelberg and the Charité Medical School of Berlin in Germany, the University of Manchester in the UK and the University of Uppsala in Sweden.
Treatment scheme: Patent • Prof. Ulrich von Arnim holds worldwide patent for the new treatment scheme • Assessment of specialized financial auditor Ralph Villiger, Avance, Basel GmbH estimates value of patent at 1 billion Euros (start of commercialization)/10 billion Euros (terminal value possible)
Treatment scheme: Costs • Total costs estimated with 65,000 Euros, incl. 17,000 Euros for the medications per treatment and patient • Probability of more than 98% that treatment will be covered by German statutory health system (GKV) (acc. to leading law firm Clifford Chance) • Insulin dependent diabetes is primarily defined as a childhood disease • 90% of medications prescriptions for children are off-label (acc. to leading health insurer AOK) • Additionally sustainable cost savings of more than 100,000 Euros per patient’s lifetime will lead to acceptance and support by health insurers. • Cost analysis will start in cooperation with German University end of 2010, results will be the basis for negotiations with health insurers.
BvA-TeC: Gives access to new treatment scheme BvA-TeC will befoundedtocommercialize the patented treatment scheme on a worldwide scale: • Sellinglicensestomanufactureandmarketthemedications • Training, supportandconsultingofdoctorswhotreatpatientsworldwide • Treatment andtestingofpatientsatown model hospitals/laboratories • Research & developmentatownhospitals/laboratories • Effectivemarketing & communicationworldwidetocreate a strong demandandmakethenewtreatmentbecoming a standardpractice
BvA-TeC: Initiators/Managers Prof. Ulrich von Arnim (born 1960) • Doctoral thesis in London on multiple sclerosis diagnostics • Managing director of WISRO International, a successful biotech company • Department of Biochemistry and Molecular Biology at Monash University in Melbourne Larry Green (born 1950) Peter Schiftan (born 1941) David Meggs (born 1949)
VA Holding S.E. Intellectual Property Holder Licence FeesDividends 94,00% Dividends DIARESOLVE Holding S.E. Business Management BvA-TeC S.E. Design, Licensing, Manufacturing, Distribution of Test Kit BvA-TeC: Structure 6,00% GmbH Germany Corp. USA Hospital Hospital Licensing Training Center Training Laboratory Laboratory
Cooperation with pharmaceutical companies: Market potential • Currently about 90 million diabetes type-1 and -1.5 patients worldwide • Increase by 2.5% per year to about 380 million diabetes patients until 2025 (WDF) Source: International Diabetes Federation and own calculation. Incidence and prevalence for type 2 refer to adults of age between 20 and 79 years (4.3 bn. worldwide).
Cooperation with pharmaceutical companies: Potential sales Additional sales of 57 billion Euros within 10 years with existing medications
Offer for pharmaceutical companies • SICAR fund with a total volume of 2 billion Euros • Participation in licensing agreements through SIF cell • Non-asset-shares of BvA-TeC (10%-share) • Licenses to manufacture and market the used medications tbd.
